Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RUN and SH3 domain containing protein 2 (RUSC2) is a cytoplasmic protein characterized by the presence of RUN and SH3 domains. It interacts with the small GTPase Rab1b and its binding partner GM130 and associates with the adaptor protein complex 4 (AP-4)[1][3][5][7][10]. RUSC2 appears to participate in protein vesicular trafficking, particularly at the trans-Golgi network, potentially acting as an accessory or adaptor component in sorting or transport functions[1][3][7]. Mutations in RUSC2 are linked to rare inherited intellectual developmental disorders and syndromic conditions involving the nervous and digestive systems[1]. There is currently no evidence in the literature or main gene/protein databases that RUSC2 is a direct therapeutic target, nor are there any known drugs or biomarker applications associated with this protein[1][3][5][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RUN and SH3 domain containing protein 2 (RUSC2).